The efficacy of <font color="blue">prophylactic_1</font> <font color="blue">ondansetron_2</font> <font color="blue">,_2</font> <font color="blue">droperidol_2</font> <font color="blue">,_2</font> <font color="blue">perphenazine_2</font> <font color="blue">,_2</font> <font color="blue">and_1</font> <font color="blue">metoclopramide_2</font> in the prevention of nausea and vomiting after major gynecologic surgery . 
<br>
<br> The prophylactic antiemetic efficacy of <font color="blue">intravenous_1</font> <font color="blue">(_1</font> <font color="blue">i.v_1</font> <font color="blue">._1</font> <font color="blue">)_1</font> <font color="blue">ondansetron_3</font> <font color="blue">,_3</font> <font color="blue">droperidol_3</font> <font color="blue">,_3</font> <font color="blue">perphenazine_3</font> <font color="blue">,_3</font> <font color="blue">and_1</font> <font color="blue">metoclopramide_3</font> was evaluated in a prospective , double - blind study of 360 ASA physical status I - III patients undergoing total <font color="blue">abdominal_1</font> <font color="blue">hysterectomy_1</font> <font color="blue">(_1</font> <font color="blue">TAH_1</font> <font color="blue">)_1</font> <font color="blue">._1</font> Subjects were randomized to receive i.v . , one of <font color="blue">ondansetron_5</font> 4 mg , <font color="blue">droperidol_5</font> 1.25 mg , <font color="blue">perphenazine_5</font> 5 mg , <font color="blue">metoclopramide_5</font> 10 mg , <font color="blue">or_1</font> <font color="blue">placebo_5</font> prior to induction of <font color="blue">anesthesia_1</font> <font color="blue">._1</font> Hypotension immediately after administration of <font color="blue">metoclopramide_2</font> was observed in two patients and four patients given <font color="blue">ondansetron_1</font> developed profound systolic hypotension at induction of <font color="blue">anesthesia_1</font> <font color="blue">._1</font> Twenty - two percent of patients receiving <font color="blue">droperidol_1</font> became sedated . Postoperatively , patients developing severe nausea , retching , or vomiting , defined as severe emetic sequelae ( SES ) , were deemed to have failed antiemetic prophylaxis and received antiemetic rescue . A significantly larger number of patients who received i.v . <font color="blue">ondansetron_1</font> ( 63% ) , <font color="blue">droperidol_1</font> ( 76% ) , and <font color="blue">perphenazine_1</font> ( 70% ) were free of SES when compared to <font color="blue">placebo_1</font> ( 43% ) ; P < 0.05 . <font color="blue">Metoclopramide_1</font> was ineffective . Although <font color="blue">ondansetron_1</font> <font color="blue">,_1</font> <font color="blue">droperidol_1</font> <font color="blue">,_1</font> and <font color="blue">perphenazine_1</font> were effective in providing antiemetic prophylaxis , only i.v . <font color="blue">perphenazine_1</font> was free of side effects . Hence , we conclude that <font color="blue">perphenazine_1</font> is the best choice for antiemetic prophylaxis after <font color="blue">TAH_1</font> <font color="blue">._1</font>